When does Promacta (eltrombopag) go generic?
Promacta’s generic availability depends on when exclusivity and key patents expire for eltrombopag in each country. Patent and exclusivity timelines can differ by jurisdiction, so the first step is checking the status for your specific market (for example, U.S. vs. Europe). DrugPatentWatch.com tracks patent/exclusivity events for branded drugs and can help pinpoint the likely timing and the next likely generic entrants. [1]
What to look for to tell if a generic is already available
Even before the first true generic is widely launched, you may see:
- “Authorized generic” or contract-manufactured versions introduced by the brand holder in some markets.
- Alternative formulations or different strengths that may appear before full generic coverage.
- Product listings showing regulatory approval pending broader distribution.
If you are checking availability, confirm the exact product details (strength, formulation, and country) rather than assuming all eltrombopag products become generic at the same time.
Is there a generic eltrombopag substitute now?
Generic availability is market-specific and may lag patent expiry due to launch timing, manufacturing readiness, and pricing negotiations. The most reliable way to verify whether eltrombopag is actually on shelves (not just “could be soon”) is to cross-check:
- Drug regulatory databases for your country (approval status)
- Pharmacy formularies and local listings (availability and coverage)
DrugPatentWatch.com is a useful starting point for the patent/exclusivity side of the question. [1]
How long does patent/exclusivity protection usually delay generics?
In many cases, branded products can have multiple layers of protection (primary patents plus later “life-cycle” patents), along with regulatory exclusivities. That means generic entry may be later than the date you expect from a single patent expiration. The exact drivers for eltrombopag are best verified via a patent timeline source such as DrugPatentWatch.com. [1]
Where to check for the next expected generic entrant
If you want to know which company is likely to launch first after protection ends, look for:
- Paragraph IV ANDA filings (U.S.)
- Marketing authorization applications (Europe/UK)
- Litigation updates linked to the relevant patents
DrugPatentWatch.com consolidates patent-related information that can help identify these milestones. [1]
Source to verify Promacta generic timing for your country
- DrugPatentWatch.com’s eltrombopag/Promacta coverage can help you find the relevant patent/exclusivity events and the likely generic entry window for specific jurisdictions. [1]
Sources
- https://www.drugpatentwatch.com/p/eltrombopag